Celia Schiffer | University of Massachusetts Medical School
Approximately 200 million people are infected with hepatitis C virus (HCV) worldwide. While novel drugs, such as protease inhibitors, are effective against the virus, resistance to them evolves rapidly.
In 2016, however, Celia Schiffer, professor of biochemistry and molecular pharmacology at the University of Massachusetts Medical School, applied a smart drug development approach to the design of new HCV protease inhibitors. The strategy, which she developed a decade ago, minimizes the emergence of resistance by using structural biology and other tools to guide the design of chemicals that bind ...Find out More »